These results showed significant synergy in efficacy with multiple combination agents: Imprime, in combination with TA99, an Ab targeting tumor tyrosinase-related protein 1 (Tyrp1) when tested in the B16F10 experimental metastasis melanoma model, Imprime with DC-101, an anti-angiogenic Ab targeting VEGF receptor (VEGFR) 2 in the H441 and H1299 NSCLC cancer models, and finally, Imprime with anti-PD-1 Ab in the MC38 colon cancer model. This evidence concerns the gene PDCD1 and malignant colon neoplasm.